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About 20% of ovarian carcinomas show alterations of 19p13 and/or 19q13 in the form of added extra material whose ori-
gin often is from chromosome 11. Based on earlier spectral karyotype analysis of the ovarian cancer cell line SKOV-3,
which shows an unbalanced translocation der(19)t(11;19), the aim of this study was to determine the precise breakpoints
of that derivative chromosome. After rough delimitation of the breakpoints of microdissected derivative chromosomes by
array analysis, we designed a matrix of primers spanning 11q13.2 and 19p13.2 detecting multiple amplicons on genomic
and cDNA. Sequencing the amplicons, accurate localization of both breakpoints on both chromosomes was possible and
we found that exon 14 of HOOK2 from chromosome 19 and exon 2 of ACTN3 from chromosome 11 were fused in the
derivative chromosome. The breakpoint in the HOOK2 gene was in an intrinsic triplet of nucleic acids leading to a shift in
the ACTN3 reading frame in the derivative chromosome. This frameshift alteration should give rise to an early stop codon
causing a loss of function of ACTN3. Signals in two-dimensional Western blotting exactly match to calculated molecular
mass and the isoelectric point of the fusion protein. VC 2013 Wiley Periodicals, Inc.
INTRODUCTION
Ovarian carcinoma is the second most common
cancer in the female reproductive tract. Because
of its vague and belated symptoms, diagnosis is
usually late leading to a high mortality rate. More
than 400 karyotypically characterized ovarian car-
cinomas are listed in the cytogenetic literature
(Mitelman et al., 2012). In general, simple nu-
merical chromosomal aberrations, such as trisomy
12, are common in borderline or well-differenti-
ated carcinomas (Jenkins et al., 1993; Pejovic,
1995), whereas complex changes, including losses,
gains, unbalanced translocations, and additional
material of unknown origin in derivative chromo-
somes, are typical of poorly and moderately dif-
ferentiated carcinomas. Alterations of 19p13 and
19q13 in the form of added extra material are
among the most frequent findings (Pejovic et al.,
1989, 1992; Jenkins et al., 1993; Thompson et al.,
1994b; Micci et al., 2009, 2010). Although some
authors favor the region 19q13 being responsible
for tumor genesis anyway (Whang-Peng et al.,
1984; Bello and Rey, 1990; Thompson et al.,
1994a; Guan et al., 1995), Micci et al. (2009,
2010) have studied 37 derivative chromosomes
from 26 ovarian carcinomas using FISH-MD and
array-painting detecting two regions of primary
interest on 19p: one spanning from 20.80 Mbp to
20.85 Mbp and another more distal in 19p13.2.
They also pointed out that a particularly common
donor of added material could be traced back to
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chromosome arm 11q as seen first by Pejovic
et al. (1991, 1992).
Against the background of these findings and
those reached in previous analysis of the ovarian
cancer cell line SKOV-3 by spectral karyotyping
analysis followed by derivative chromosome
microdissection and reverse painting (Weimer
et al., 2008; Fig. 1), we have already described a
recurrent translocation and the presence of a
der(19)t(11;19)(q13.2;p13.2). Therefore in this
study, we focused on determining the precise
breakpoints of this derivative chromosome
through PCR walking and sequencing. Knowing
the involved genes could offer new insights about




The human ovarian adenocarcinoma cell line
SKOV-3 was obtained from the American Type
Culture Collection (Manassas, VA). Cells were
cultured in RPMI-1640 medium (Biochrom, Ber-
lin, Germany) supplemented with 10% fetal calf
serum (Gibco/Invitrogen, Karlsruhe, Germany),
10,000 U/ml penicillin (Biochrom) and 10,000 lg/
ml streptomycin (Biochrom). They were incu-
bated at 37C in a humidified atmosphere con-
taining 5% CO2 and dissociated by trypsin-
EDTA after growth to 80% confluence. The au-
thenticity of the cell line SKOV-3 was verified by
short tandem repeat finger print analysis using
Figure 1. PCR walking confirms the position of the fusion in the
derivative chromosome der(19)t(11;19)(q13.2;p13.2) preanalyzed by
microdissection and array painting. A: A SKOV-3 metaphase is shown
in the middle. The derivative chromosome der(19)t(11;19)
(q13.2;p13.2) isolated by microdissection (indicated by a yellow
arrow) has been identified by colocalized fluorescence signals from
chromosome 19 labeled in green and from chromosome 11 labeled
in red. Next to this metaphase, the reverse painting signals onto
normal chromosomes reveal the composition of this derivative chro-
mosome. B: The breakpoint region is further delineated by array
painting of labeled DNA from the isolated derivative chromosome
onto a 32 K BAC array being relatively placed to its corresponding
position. C: the exact breakpoint in the fusion region within the
HOOK2 gene on chromosome 19 and within the ACTN3 gene on
chromosome 11 is proved by PCR walking. The primers (green and
red boxes) are shown in the context of the exons of each gene (blue
bars). The boxes with a color gradient from green to red represent
the PCR products from genomic DNA demonstrating their starting
and ending point as well as their relative length. [Color figure can be
viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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the AmpFkSTRVR IdentifilerVR PCR Amplification
Kit (Applied Biosystems, Foster City, CA) and
compared with the database of DSMZ in
Braunschweig, Germany.
Breakpoint Pre-Localization by FISH-MD and
Reverse Painting
Initial information about relevant primer posi-
tioning was generated by isolation of the
der(19)t(11;19) from SKOV-3 by chromosome
microdissection and amplification of isolated
DNA by DOP-PCR (Weimer et al., 2000). The
amplified DNA was hybridized on normal chro-
mosomes and, in order to get higher resolution,
on a 32K BAC-tile array (Fig. 1) as well as on a
custom HD-CGH Microarray (4x44k) (Agilent
Technologies, Bo¨blingen, Germany). The signal
edges gave information about the involved break-
point. The primers of the matrix were positioned
so that their product would cross the breakpoint
from one chromosome to the other.
Genomic PCR-Matrix of Chromosome 11 and
Chromosome 19
250 ng of DNA extracted from SKOV-3 by
DNeasy Tissue Kit (QIAGEN, Hilden, Ger-
many) was utilized for long range PCR with the
Expand Long Template PCR System (Roche
Diagnostics, Mannheim, Germany). A series of 12
primers on chromosome 11 and 10 primers on
chromosome 19 were selected and spaced across
the region of interest on 11q13.2 (66284019-
66323001 bp) and 19p13.2 (12873870-12909646
bp) [Assembly: Feb. 2009 (GRCh37/hg19)].
Primer sequences are shown in Table 1. All long
range PCR reactions were performed in a volume
of 25 ll under the same mixture and cycling con-
ditions. The reagents included 1 Expand Long
Template Buffer 1, 350 lM dNTPs, 300 nM of
each primer, and 0.075 U/ll Expand Long Tem-
plate Enzyme Mix (Roche Diagnostics). In
Expand Long Template PCR Buffer 2 and 3, 500
lM dNTPs, and 0.1 U/ll enzyme mix were
adjusted. For each primer pair, long range PCR
was performed using SKOV-3—and control—
DNA as well as water instead of template as a
negative control. A positive control was per-
formed by using primer 19-B in combination with
19-A reverse amplifying a 4025 bp product origi-
nally located on chromosome band 19p13. Long
range PCR was carried out using Thermocycler
MJ Research PTC-200 (Biozym, Hess. Oldendorf,
Germany) and touchdown PCR as previously
described by Don et al. (1991): 92C for 2 min,
nine cycles of 92C for 10 sec, 68–60C for 30 sec
with 1C each cycle, and 68C for 5 or 10 min
(depending upon the expected product—1 kb
needs 1 min), followed by 24 cycles of 92C for
15 sec, 60C for 30 sec, and 68C for 5 or 10 min,
and 68C for 7 min. Products were analyzed on
standard 0.8% agarose gels (80 volts for 50 min)
and stained with ethidium bromide.
Once a putative breakpoint had been recog-
nized by generating a PCR product, the accurate
characterization of this region was subsequently
validated using additionally designed primers ad-
jacent to the proposed junctions. Primer sequen-
ces are also listed in Table 1. Amplifications were
performed using Thermocycler MJ Research
PTC-200 (Biozym, Hess.Oldendorf, Germany) in
25 ll reactions containing 10 ng/ll DNA, 1
PCR buffer, 25 mM MgCl2, 200 lM dNTPs, 300
nM of each primer, and 0.025 U/ll AmpliTaq
DNA Polymerase (Applied Biosystems, Darm-
stadt, Germany), with the following cycling pa-
rameters: 94C for 2 min, nine cycles of 91C for
30 sec, 68–60C for 30 sec with 1C each cycle
and 70C for 2 or 3 min, and 24 cycles of 91C
for 30 sec, 60C for 30 sec and 70C for 2 or 3
min, and 72C for 5 min. Expecting larger prod-
ucts, long range PCR with the Expand Long
Template PCR System (Roche Diagnostics) was
also done under the aforementioned conditions
with an elongation time of 5 min. Products were
separated on 0.8% agarose gel (80 volts for 50
min) for larger products or on 2% agarose gel
(100 volts for 35 min) for smaller product until 3
kb. Both were visualized with ethidium bromide.
PCR of Gene Related Primers on cDNA
RNA was extracted from SKOV-3 using
RNeasy Mini Kit (QIAGEN) and 2 lg RNA was
utilized for reverse transcription using Super-
Script III First-Strand Synthesis SuperMix (Invi-
trogen) and DNA Polymerase I (Invitrogen)
according to the manufacturer’s instructions. We
used the primers Hk2/Ac3 forward and Hk2/Ac3
reverse (Table 2). All PCRs based on cDNA
were performed in the Thermocycler MJ
Research PTC-200 (Biozym) with two enzymes:
First, 0.025 U/ll Discoverase DNA Polymerase
(Invitrogen) was mixed with 1 PCR buffer, 50
mM MgSO4, 200 lM dNTPs, 300 nM of each
primer, and an unknown amount of cDNA. Sec-
ond, 0.025 U/ll TaKaRa Ex Taq DNA
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Polymerase (TaKaRa Bio Europe S.A.S, Potsdam,
Germany) was added to 1 PCR buffer, 25 mM
MgCl2, 200 lM dNTPs, 500 nM of each primer,
and an unknown amount of cDNA. Because of
the unknown amount of cDNA, tests with differ-
ent cDNA volumes were performed using both
enzymes. Using Discoverase DNA Polymerase,
the conditions for the PCR reaction were 94C
for 1 min, 17 cycles at 94C for 45 sec, 66–58C
for 30 sec with 0.5C each cycle and 72C for 1
min, followed by 15 cycles at 94C for 45 sec,
58C for 30 sec, and 72C for 1 min, and finally,
TABLE 2. Sequences of the Primers Hk2/Ac3
Primer Chromosome Sequence Tm
Hk2/Ac3 forward 19 50-CTC CAC ACC CGT GGA TAA CT-30 60C
Hk2/Ac3 reverse 11 50-CAG GAG CAG CAT GAG TTT GA-30 58C
Tm, temperature.
TABLE 1. Primer Sequences and Positions on Chromosomes 11 and 19
Primer Gene Sequence Tm
11-1 forward Positive control 50-ATC TCT TTT GGG GAA GGG TAG G-30 62C
11-1 reverse BBS1 50-TAG AGA AAA CCC CTT CCC ATC C-30 62C
11-2 BBS1 50-TAC CCA GAA CTA ACT GTG GAG C-30 62C
11-3 BBS1/ZDHHC24 50-TGA CCC TCC TCT GTC TAA ACC T-30 62C
11-4 BBS1/ZDHHC24 50-TGG ATT TGC AGA GGT GAG TGA C-30 62C
11-5 BBS1/ZDHHC24 50-CTC CTC TGC ATC TAT CCA CTC T-30 62C
11-6 ZDHHC24 50-AAA CAG TCC TCA GTG AAG CAG G-30 62C
11-7 ZDHHC24 50-TAT GTG TTC CCA AAA GGT GGG G-30 62C
11-8 ZDHHC24 50-GCC TCA GGA CCT TCA AAC AGA A-30 62C
11-9 ZDHHC24 50-CAG AGG CTT TTG CTG AGA CTG A-30 62C
11-10 ACTN3 50-GAC TGC AAG TTG GGA TGA ACA G-30 62C
11-10/1 50-TGT TGG GAT TAC AGG CAT GA-30 56C
11-11 ACTN3 50-TCA CCT TCA GCA CCA ATG GAC A-30 62C
11-11F1 50-CGA GGC AGG GAT TAT TCT CA-30 58C
11-11R1 50-AGG TGG CAG GAA GGG TCT T-30 59C
11-11F2 50-CAT TGC TCA CCT TCC ACA GA-30 58C
11-11R2 50-GAG GCC AGA TAG CAC AGA CC-30 63C
11-11F3 50-ACG ATT CCG TCA CAC ACT CA-30 58C
11-11R3 50-TCT CTG TCA CAA GCC ACA GG-30 60C
11-12 ACTN3 50-GAC AAG ATA GAG GAC TCC TGG A-30 62C
19-A forward HOOK2 50-CTC TCT CTG GAG TTC ATG TGC T-30 62C
19-A reverse Positive control 50-AGC ACA TGA ACT CCA GAG AGA G-30 62C
19-AF1 50-CTG GCA TCT CTG AAC CTT CG-30 60C
19-AR1 50-AAT CTG GGA GAG GGA AGA GC-30 60C
19-AF2 50-GAA GCG GGA GTA CAT TGA GG-30 60C
19-AR2 50-GCG TCC TTC TTC TGC AAG TT-30 58C
19-AF3 50-GCT AGC AAG GGA AGA TGG TG-30 60C
19-AR3 50-CCA GTG GTA GCC ACA GAC CT-30 63C
19-AF4 50-CCC GAA GTA ACC CTC CTC TC-30 63C
19-AR4 50-TTC CTC CAG CTT CCT TTT CA-30 56C
19-AF5 50-AAA ACC CCG AAA AAC TGT CC-30 56C
19-AR5 50-AGC ACC GAG GAC CTA CTA CG-30 63C
19-B HOOK2 50-TCT GTG AGT TTC AGT CCC CTG T-30 62C
19-BC1 50-TTG TGT CCC AGT GCA TGT CT-30 58C
19-BC2 50-TGG AGG TGA CCA GAA AGA GG-30 60C
19-C HOOK2 50-AAC CTG TTT CCA GAG TTC CCC T-30 62C
19-D HOOK2 50-TGC TGA ACC AGA TGT GAG TGG A-30 62C
19-E Intron 50-TTG TAA CAG CTG TGG TTC CTG G-30 62C
19-F Intron 50-GCT GTC CTC TGT GAC TTT GAC T-30 62C
19-G Intron 50-GCA CAG GAT AAG GAG GAA GTT C-30 62C
19-H Intron 50-TCC CTT CCT TAG AAA CAG GCT G-30 62C
19-I JUNB 50-CTG TTT TTC TCC ACT GCT CTG G-30 62C
19-J PRDX2 50-TGT CTC ATG CCT GTA GAT GCT G-30 62C
Tm, temperature.
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72C for 5 min. Concerning TaKaRa Ex Taq
DNA Polymerase, the conditions for the PCR
reaction were 94C for 1 min, nine cycles of 94C
for 30 sec, 66–58C for 30 sec with 1C each
cycle and 72C for 1 min, and 23 cycles of 94C
for 30 sec, 58C for 30 sec, and 72C for 1 min,
and finally, 72C for 5 min. Products were detect-
able on 2% agarose gels (100 volts for 35 min)
stained with ethidium bromide. The purified
amplicon was used as template for confirming the
fusion gene HOOK2/ACTN3 under the same con-
ditions using the enzymes Discoverase DNA Po-
lymerase and TaKaRa Ex Taq DNA Polymerase
with 3 ll of cDNA.
Sequencing of Fusion Products
The identity of the following PCR products
was confirmed by complete sequencing of the
purified products through company MWG-Euro-
fins: 11-12/19-B, 11-11/19-B, 11-11F2/19-B, 11-
11F1/19-B, and 11-11/19-BC1 from genomic
DNA and Hk2/Ac3 from cDNA. Nucleotide posi-
tions of the breakpoints and human master
sequences are given according to UCSC Genome
Browser. The analysis of sequences was done by
BioEdit Sequence Alignment Editor Software
Ver. 7.0.9.0 (Hall, 1999).
Calculation of Theoretical pI and
Molecular Mass Values
The theoretical pI and molecular mass of both
native HOOK2 and the HOOK2-ACTN3 fusion
proteins were calculated based on the predicted
amino acid sequence using the ExPASy Bioinfor-
matics Ressource Portal (http://web.expasy.org/
compute_pi/).
Two-Dimensional Western Blot
SKOV-3 cells and unobtrusive ovarian epithe-
lial cells were grown to full confluency in T75
cell culture flasks and harvested using a cell
scraper. Cells were washed three times with PBS
and lysed in two-dimensional (2D)-lysis buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 30 mM
Tris, pH 8.5). Cell lysates were sonified and cen-
trifuged at 4C for 15 min at 25,000g. Superna-
tants were collected and stored for 2D separation
at 20C.
150 lg of protein per sample were combined
with one volume of 2D-sample buffer (7 M urea,
2 M thiourea, 4% CHAPS) and subjected to 2D
separation. Isolelectric focussing was performed
at 20C for 31,000 kVh on rehydrated 13 cm
ImmobilineTM DryStrips (pH 3–11 NL, GE
Healthcare, Munich, Germany) using Ettan IPG-
phor 3 electrophoresis equipment (GE Health-
care). For the second dimension, DryStrips were
equilibrated in 75 mM Tris, 6 M urea, 2% SDS,
30% glycerol, and a trace of bromophenol blue
with dithiotreitol for the first 15 min and iodo-
acetamide for additional 15 min. The equilibrated
DryStrips were then placed onto 12.5% polyacryl-
amide gels and covered with 1% LMP agarose/
SDS running buffer. SDS-PAGE was performed
by applying 25 mA per gel until the bromophenol
blue front reached the bottom of the gel.
Subsequently, proteins were transferred to
HybondTM-C Extra nitrocellulose membranes
(GE Healthcare RPN303E) by applying 10 mA
per gel overnight at 4C. Transferred proteins
were visualized by staining proteins with
SYPROVR Ruby protein Blot Stain (Invitrogen
S11791) following the manufacturer’s instructions.
Fluorescence emission was recorded using a Ty-
phoon TRIO laser scanner (GE Healthcare, set-
tings: 610 BP 30, 470 PMT). HOOK2 protein on
2D Western blots was stained using polyclonal
rabbit-anti-HOOK2 antibodies (GeneTex;
GTX115898, 1:500, 16 h, 4C) and donkey-anti-
rabbit HRP-conjugated secondary antibodies (GE
Healthcare; NA9340V, 1:5,000, 45 min, room
temperature). For detection, membranes were
incubated for 1 min with AmershamTM ECLTM
Western Blotting Detection Reagents (GE
Healthcare RPN2106) and resulting chemolumi-
nescence was detected using Amersham Hyper-
filmTM ECL (GE Healthcare).
RESULTS
PCR-Matrix of Chromosomes 11 and 19 on
Genomic DNA
After narrowing down the potential breakpoint
region of the microdissected derivative chromo-
some der(19)t(11;19)(q13.2;p13.2) from the ovar-
ian adenocarcinoma cell line SKOV-3, to various
arrays, we performed PCRs across the potential
genomic breakpoint using a panel of primers on
each side of the breakpoints. Using various com-
binations of primers, amplicons of 6.2 kb and 2.4
kb could be generated combining primers 11–12
and 19-B and 11–11 and 19-B, respectively (Figs.
1 and 2). The breakpoint region was further
delineated using different internal primer sets,
for instance 11–11F3/19-B showing a 5.7 kb
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amplicon, 11–11F2/19-B showing a 4.9 kb ampli-
con, and 11–11F1/19-B showing a 2.5 kb ampli-
con (Figs. 1 and 2). Primer combination 11–11/
19-BC1 or 11–11/19-BC2 produced an amplicon
of 3 kb (Figs. 1 and 2).
Sequencing of the 11–11 and 19-B amplicon
revealed the breakpoint junction to be located
between exons 14 and 15 of HOOK2 on chromo-
some 19 and between exons 1 and 2 of ACTN3
on chromosome 11. Between these neighboring
exons in each gene, the breakpoint could be any-
where in a homologous sequence of 21 nucleo-
tides on chromosome 11 at 66317105-66317126
and on chromosome 19 at 12877492-12877513
(Fig. 3). The fusion gene extends form the first
exon of HOOK2 over the end of exon 14 origin
on chromosome 19, and continue with second
exon of ACTN3 until its end origin on chromo-
some 11.
Using a set of reciprocal primers, we could not
verify any reciprocal translocation products corre-
sponding to the translocation which confirmed
the unbalanced nature of the rearrangement at
the molecular level.
PCR of Gene-Related Primers on Genomic and
cDNA
Additionally, primers Hk2/Ac3 forward and
reverse located in exons next to those bridging the
fusion generated an amplicon of 2.454 kb with
genomic DNA as template (Figs. 1 and 2). Using
cDNA as template, light amplicons of 394 and 320
bp were detected beside a strong amplicon of 154
bp by these primers (Fig. 4). Sequencing of this
isolated 154 bp amplicon confirms the fusion of
HOOK2 with exon 2 of ACTN3 coded on chromo-
some 11. The precise intronic breakpoint position
Figure 2. Electrophoresis gels of products from PCR walking on genomic DNA. The template DNA
is given at the top; the primer combinations are listed below each line.
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on genomic DNA is consequently confirmed by
spliced mRNA sequences revealing exon14 of
HOOK2 and exon 2 of ACTN3 to be involved.
Probable Amino Acid Sequence in the Fusion
Gene
The human genomic database UCSC hg19 illus-
trates the original wild type mRNA of HOOK2
ending on exon 14 with two coding nucleotides
and continuing on exon 15 with the third coding
nucleotide, which together encodes the amino acid
arginine (AGG). The sequence in exon 2 of the
native wild type ACTN3 starts with the complete
triplet (ACC) for threonine and continues with
(TTC) for phenylalanine on exon 2.
In the spliced der(19)t(11;19), the two last cod-
ing nucleotides ‘‘AG’’ on exon 14 of HOOK2 are
fused with the first codon (ACC) in exons 2 of
ACTN3. The first nucleotide of this codon does
complete the last nucleotides of exon 14 in
HOOK2 and leads to a frameshift in the ACTN3
part of the fused gene. This fusion spanning reor-
ganized triplet codes for arginine (AGA) as
before. Shifted by one nucleic acid the code for
amino acids continues with proline (CCT) and
serine (TCA) in a shifted frame (Fig. 4).
Provided an equal splicing procedure of the
translocated ACTN3 rest, in theory the first stop
codon (TGA) receiving this shifted reading frame
starts in a distance of 253 nucleotides down-
stream the fusion location on exon 4 of the
ACTN3 rest.
Detection of the Putative Fusion Protein by 2D
Western Blotting
The 2D Western blot of lysate from unobtru-
sive ovarian epithelial cells revealed prominent
protein spots at the expected molecular mass of
85 kDa using the polyclonal anti-HOOK2 anti-
body (Fig. 5A). When using comparable exposi-
tion times for detection, this area was much less
intensely stained using lysate from SKOV-3 cells.
Of note, several other protein spots were stained
by this polyclonal antibody with similar intensity
Figure 3. Sequence of the PCR product 19-B and 11–11 on
genomic DNA. The upper (19-B) and lower (11–11) sequence repre-
sents the primer sequences highlighted with green (line 1) and red
(line 5), respectively. The master sequences of homologues in the
breakpoint region of chromosome 19 and 11 are shown next to
them (lines 2 and 4). The sequence of the product 19-B/11–11 is
shown in line 3. Homologies with its origin of chromosome 19
(green) and 11 (red) are shown as rectangles. Thus, the fusion is
located anywhere in the coherent homologue region of both chro-
mosomes across 21 nucleotides shared by chromosome 19 and chro-
mosome 11. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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on both immunoblots. However, as can be seen
in Figure 5B, in SKOV-3 lysate, a unique protein
patterns appeared that was not stained in ovarian
epithelial cells (Fig. 5A), nor in fibroblasts used
as a further control (not shown). The apparent
molecular mass of these unique spots exactly fits
the calculated molecular mass (61 kDa) of the
expected fusion protein. In addition, also the the-
oretical pI of 5.3 of the expected fusion protein
matched the pI area of the detected spots on the
2D Western blot, providing substantial evidence
for the translation of the fusion protein in trans-
formed SKOV-3 cells.
DISCUSSION
Our own data as well as those described in the
literature reveal the presence of a translocation
product between chromosomes 11 and 19 in
some ovarian carcinomas, which has been further
analyzed by SKY, FISH-MD, and RevISH
(Weimer et al., 2008; Micci et al., 2009) using iso-
lated chromosomes. Subsequent array CGH anal-
ysis of microdissected chromosomes yielded
results precise enough to start molecular analysis
(Micci et al., 2010). The findings indicated that
the breakpoints often occurred in a region within
the possible target genes BBS1, ZDHHC24, or
ACTN3 in chromosome subband 11q13.2 and
within HOOK2, JUNB, or PRDX2 in chromosome
sub-band 19p13.2 (Weimer et al., 2008). In this
study, we successfully mapped the fusion sequen-
ces of the der(19)t(11;19)(q13.2;p13.2) present in
the ovarian cancer cell line SKOV-3. Diverse
genomic PCR products demonstrated the break-
points as illustrated in Figures 1 and 2. The
fusion is located between exon 14 of HOOK2 and
exon 2 of ACTN3 (Fig. 3). The translocation in
der(19)t(11;19)(q13.2;p13.2) induces a fusion
between HOOK2 and ACTN3 resulting in a loss of
specific exons. Presumably, this fusion leads to a
change or even loss of function of the encoded
Figure 4. Sequence of the PCR product Hk2/Ac3 forward and
Hk2/Ac3 reverse on cDNA in comparison to the master sequences
of exon 14 in HOOK2 and of exon 2 in ACTN3. A: Electrophoresis of
the fusion PCR products generated by exon spanning primers Hk2/
Ac3. B: Sequence of the fusion cDNA product by Hk2/Ac3 primers
in comparison to the master sequence of exon 14 in HOOK2 and
exon 2 in ACTN3. C: Comparison of the exons’ spanning sequence
and its meaning for amino acid coding in original and fusion genes.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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proteins. As shown in Figure 4, the order of
amino acids is completely changed by a shifted
reading frame in the ACTN3 part of the fusion
cDNA as a result of the translocation. This
change is caused by the first nucleotide on exon
2 in ACTN3 which fulfills the last uncompleted
codon in exon 14 of HOOK2. The composed
codon still encodes arginine as before, but the
following triplets of nucleic acids in the ACTN3
part now encode proline and serine different to
those coded originally in the wild type. Conse-
quently, the frameshift in ACTN3 leads to altered
translation and presumably a loss of function due
to an early stop codon which can be found 253
nucleotides downstream the fusion on exon 4 in
ACTN3 part. The calculation of the theoretical
molecular masses and isoelectric points of the
HOOK2-ACTN3 fusion protein and the native
HOOK2 protein based on the predicted amino
acid sequences indicated that both proteins dis-
play a very similar pI but significantly differ in
the molecular masses, the fusion protein being
20 kDa smaller than the native HOOK2 protein.
Clearly, a series of protein spots at a molecular
mass of approximately 60 kDa also fits to the the-
oretical pI value of the predicted fusion protein
(Fig. 5). As these spots were only detected in the
SKOV-3 cells, they are likely to represent the
HOOK2-ACTN3 fusion protein. It remains
unclear whether the function of the HOOK2 part
of the fusion protein is disturbed by the
translocation.
HOOK-related proteins may act as linker pro-
teins for transport along microtubules, as contrib-
utors to aggresome formation, as components of
centrosomes, and direct anchors of organelle
transport (Walenta et al., 2001; Malone et al.,
2003; Szebenyi et al., 2007b). They control spin-
dle organization and cytokinesis during mitosis
(Bornens, 2002; Doxsey et al., 2005). Only an
intact microtubule cytoskeleton linked by HOOK
proteins enables dynein-mediated retrograde
transport of misfolded proteins to the aggresome
and thus structural integrity of cells (Garcia-Mata
et al., 2002; Gunawardena et al., 2003; Malone
et al., 2003). The ability of connecting different
molecules can be traced back to the structure
which consists of the conserved N-terminal do-
main of HOOK for attachment to microtubules
and the C-terminal domain mediates binding to
organelles (Walenta et al., 2001; Szebenyi et al.,
2007a). Failures in these functions may jeopard-
ize cell structure and form (Walenta et al., 2001;
Mendoza-Lujambio et al., 2002; Guthrie et al.,
2009). Since the used antibody apparently detects
the fusion protein, the conserved N-terminal do-
main distal to immunogen position still seems at
least to be intact. It may be accepted that the C
terminal domain of the HOOK2 part in the
fusion protein has no or only a restricted function.
However, Szebenyi et al. (2007a) showed that
HOOK proteins share target signals and that
some functions can be compensated for in case of
mutations as demonstrated for HOOK2 and
HOOK3. It is conceivable that failure of function
induces apoptosis in preneoplastic cells if uncom-
pensated for (Rufini and Melino, 2011). Loss of
exons 15–22 of HOOK2 could cause an altered
protein expression of HOOK2 which may destroy
cell organelles or influence cell cycle control sta-
tions. It has also been demonstrated in Drosoph-
ila that truncated HOOK proteins dimerize with
endogenous HOOK and inhibit its function
(Kramer and Phistry, 1996). Abnormal positioning
of the centrosome could lead to segregation
defects of chromosomes with subsequent aneu-
ploidy (Pihan et al., 1998). The correlation
Figure 5. 2D Western Blot analysis of (A) unobtrusive epithelial
ovarian cells and (B) SKOV-3 cells. Although unobtrusive ovarian epi-
thelial cells strongly express native HOOK2 protein (see arrow; MW
5 83 kDa, pI 5 5.36), its expression is decreased in SKOV-3 cells.
Protein spots at a molecular weight of approximately 60 kDa, which
are unique for SKOV-3 cells could match the theoretical HOOK2-
Actinin3 fusion protein (see rectangle; MW 5 61.5 kDa, pI 5 5.34).
Values on the left side of each Western Blot indicate relative molecu-
lar masses [kDa] according to the All Blue Prestained Protein Stand-
ard (BioRad). Numbers on the top indicate the pH values.
520 ONKES ETAL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
between centrosome amplifications or dysfunc-
tions and chromosomal instability has already
been shown in various cancers such as prostate
and breast cancer (Miyoshi et al., 2001; Pihan
et al., 2001, 2003). Loss of the C-terminal organ-
elle binding domain very likely causes functional
loss of the HOOK2 components in the fusion
gene, even if the conserved N-terminal microtu-
bule binding domain retains its function.
Even if the function of the ACTN3 part may
be excluded in the fusion protein, the frameshift
leads at least to a copy loss which might have
general functional and cell biological consequen-
ces. ACTN3 encodes an alpha actin-binding pro-
tein which belongs to a highly conserved family
related to dystrophin and the spectrins (Blanchard
et al., 1989; Beggs et al., 1992; Djinovic-Carugo
et al., 2002; MacArthur and North, 2004). It also
interacts with various proteins involved in signal-
ing and metabolic pathways although this is
shown more clearly for ACTN2 (MacArthur and
North, 2004). Its expression is restricted to fast
glycolytic skeletal muscle fibers in which it plays
a part in major structural components of the Z-
line involved in anchoring the actin-containing
thin filaments (Beggs et al., 1992; Gimona et al.,
2002). Their contribution to the orderly disassem-
bly of cell-cell junctions required for cell migra-
tion has been demonstrated in human breast
cancer cells (Guvakova et al., 2002; Otey and
Carpen, 2004). Because of the frameshift in this
translocated ACTN3 allele, it may be assumed
that this allele has lost its function.
In summary, we identified at the molecular
level the breakpoint of the unbalanced transloca-
tion der(19)t(11;19)(q13.2;p13.2) in the ovarian
cancer cell line SKOV-3 showing that the translo-
cation led to a fusion of the genes HOOK2 and
ACTN3. We detected a C-terminal truncation in
the HOOK2 part and a frameshift in the ACTN3
part in cDNA after gene fusion resulting in an
early stop caused by the translocation and leading
to a loss of function. The calculated molecular
mass and the isoelectric point of the expected
fusion protein exactly match to the signal of the
fusion protein detected by 2D Western blotting.
It remains unclear, however, how far the function
of HOOK2 is disturbed by the C-terminal trunca-
tion. Possibly, the truncation affects microtubule
functions such as the retrograde transport of
misfolded proteins to aggresomes and their degra-
dation as well as centrosomal structures leading
to genetic instability. Thus, future investigations
will focus on the protein product of the fusion
between HOOK2 and ACTN3 in SKOV-3 cells
and the impact of this alteration for tumor cell
biology.
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